Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

3 Things Pfizer's New CEO Just Said That Investors Will be Glad to Hear

By Keith Speights - Updated Apr 15, 2019 at 2:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pfizer's new CEO, Albert Bourla, provided reasons for shareholders to cheer at the J.P. Morgan Healthcare Conference on Monday.

Check out the latest Pfizer earnings call transcript.

For the first time in eight years, a new Pfizer ( PFE -3.25% ) CEO took the stage at the J.P. Morgan Healthcare Conference. Albert Bourla took the reins from Ian Read only a few days ago. He and Mikael Dolsten, head of research and development for Pfizer, sat down to field questions at the conference on Monday.

There was plenty of discussion about Pfizer's pipeline and drug pricing. But three things that Pfizer's new CEO said at the J.P. Morgan conference should especially make shareholders happy. 

Man with hand cupped to his ear

Image source: Getty Images.

1. We'll keep growing the dividend

Pfizer boosted its dividend in December by 6%. The dividend now yields nearly 3.4%. When Ian Read was CEO, Pfizer repeatedly affirmed that its top capital allocation priority was the dividend. So what does Bourla think about dividends?

He was asked the same question that Read had to answer many times in the past about capital allocation. And Bourla's response was the same as his predecessor's. He stated that Pfizer's top priority has been growing the dividend and that the company will "maintain this policy."

That should be music to the ears of Pfizer shareholders, many of whom were attracted to the stock in the first place because of its strong dividend. Investors who bought Pfizer shares 10 years ago and held on now have an effective dividend yield of over 8% because of dividend increases -- more than double the yield they started out with. Bourla's commitment to continue growing the dividend should mean those effective yields are only going to become more attractive.

2. We'll keep on buying back shares

Another top capital allocation priority for Pfizer during Read's tenure as CEO was share repurchases. In the first three quarters of 2018, Pfizer bought back $7.2 billion of its stock. And one of the final actions Pfizer's board of directors took while Read remained chairman was to authorize a new $10 billion buyback program.

Bourla has the same view about share buybacks as Read did, saying at the J.P. Morgan conference that Pfizer will continue its practice of repurchasing shares. He referred to buybacks as "investing in ourselves." With Pfizer's shares trading at only 14 times expected earnings, that should be a pretty good investment for the company.

It's also a good investment for shareholders. Every share Pfizer buys back makes existing shares worth more, with all other factors remaining constant. Stock buybacks are kind of an "invisible dividend" that rewards shareholders -- and they don't even have to pay taxes on them.

3. We'll do deals -- but not distracting ones

Pfizer has been very active on the business development front in years past. It has made big deals including the buyouts of Hospira and Medivation. Pfizer also attempted to gobble up Allergan in 2016 before throwing in the towel after the U.S. Treasury Department wiped out the tax benefits from the deal. But over the past two years, the company hasn't made any major acquisitions.

What's the company's new CEO's stance on deals? Bourla said Pfizer will continue to invest in opportunities. However, he added that he doesn't want a distraction. Instead, Bourla indicated that Pfizer will focus on bringing phase 2 and phase 3 assets into its pipeline that target therapeutic areas on which the company currently focuses.

This approach is good news for investors. Focusing on its areas of expertise should improve the odds that Pfizer picks the right candidate drugs to acquire. And buying select targeted assets rather than making a massive acquisition means Pfizer's balance sheet should remain healthy, which helps the company keep growing its dividends and buying back more shares. 

Looking ahead

It's too early to say whether Bourla will be a great CEO for Pfizer. But his commitment to stay the course Read set when it comes to capital allocation is encouraging.

Bourla inherits a company that arguably has its strongest pipeline in years. Pfizer has 15 programs with blockbuster potential. It also faces challenges, notably including the continued negative impacts from drugs that have or will lose exclusivity. However, the overall story for Pfizer and its prospects appears to be pretty good right now. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$52.91 (-3.25%) $-1.77

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.